Focused On-demand Library for Arginine--tRNA ligase, cytoplasmic

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P54136

UPID:
SYRC_HUMAN

ALTERNATIVE NAMES:
Arginyl-tRNA synthetase

ALTERNATIVE UPACC:
P54136; B2RBS9; Q53GY4; Q9BWA1

BACKGROUND:
The Arginine--tRNA ligase, cytoplasmic, identified by the alternative name Arginyl-tRNA synthetase, is integral to the protein synthesis machinery. It ensures the precise attachment of arginine to tRNAs, facilitating correct protein formation. Its role extends beyond synthesis, affecting inflammatory pathways through modulation of AIMP1 secretion and EMAP2 cytokine production.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Leukodystrophy, hypomyelinating, 9, Arginine--tRNA ligase, cytoplasmic's involvement in this genetic disorder highlights its therapeutic relevance. Targeting this protein could lead to novel treatments for the disease, emphasizing the importance of research into its functions and mechanisms. Understanding the role of Arginine--tRNA ligase, cytoplasmic could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8611 of 8789